Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 3/20 | 0.51 |
| ▸ | BCL9 | O00512 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421378 | 0.93 | BCL9 (0.53) | LMNAACHEBCL9CTNNB1KMT2A | |
| SCHEMBL9716532 | 0.87 | KMT2A (0.56) | LMNACYP3A4ACHEKMT2AALDH1A1 | |
| SCHEMBL1820340 | 0.86 | MTNR1B (0.55) | LMNA | |
| SCHEMBL28396900 | 0.86 | LMNA (0.65) | LMNACYP3A4ACHEKMT2AMEN1 | |
| SCHEMBL27383473 | 0.85 | BCL9 (0.62) | LMNACYP3A4BCL9CTNNB1KMT2A | |
| SCHEMBL28527742 | 0.85 | LMNA (0.49) | LMNACYP3A4ACHEBCL9CTNNB1 | |
| SCHEMBL4810160 | 0.84 | LMNA (0.62) | LMNAACHEBCL9CTNNB1KMT2A | |
| SCHEMBL10771577 | 0.83 | MTNR1B (0.51) | LMNAKMT2AKDM4EALDH1A1PDGFRB | |
| SCHEMBL17028900 | 0.83 | LMNA (0.76) | LMNACYP3A4ACHEKMT2AKDM4E | |
| SCHEMBL249305 | 0.83 | LMNA (0.76) | LMNACYP3A4ACHEKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | NUDT1, PNP, ATIC | LMNA 4604/4885CYP3A4 1370/4885ACHE 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.